SNDX

Business Context and Reporting Period

Company: Syndax Pharmaceuticals, Inc. (SNDX)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal Year Ended December 31, 2025
Business Overview: Syndax is a commercial-stage biopharmaceutical company focused on cancer therapies. It currently markets two FDA-approved medicines: Revuforj (revumenib), a menin inhibitor for acute leukemia, and Niktimvo (axatilimab-csfr), a CSF-1R blocking antibody for chronic graft-versus-host disease (cGVHD). The company operates as a single segment and relies on third-party manufacturers and collaboration partners, notably Incyte Corporation for Niktimvo.

Key Financial Metrics

Note: The filing text does not provide explicit gross margin percentages, but Cost of Product Sales was $7.0 million in 2025 compared to $124.8 million in product revenue.

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased by $148.7 million (628%) year-over-year, driven primarily by the commercial launch of Revuforj and Niktimvo. Net product revenue surged from $7.7 million to $124.8 million.
• Collaboration Revenue: The company recognized $42.4 million in collaboration revenue in 2025, representing its share of net profits from Niktimvo sales with Incyte. No such revenue was recognized in 2024 as Niktimvo launched in early 2025.
• Expense Increases:
  • SG&A: Increased by $58.8 million to $179.7 million, largely due to commercial launch costs ($20.1 million increase) and higher personnel costs ($24.4 million increase) to support sales and marketing.
  • R&D: Increased by $17.1 million to $258.8 million, driven by new clinical trials for Revuforj in newly diagnosed patients and higher personnel costs.
• Net Loss Improvement: Net loss narrowed by $33.3 million to $285.4 million, despite higher operating expenses, due to significant revenue growth.
• Financing Activity: In November 2024, the company entered a royalty financing agreement with Royalty Pharma, receiving $350 million upfront. This resulted in $33.8 million of royalty interest expense in 2025.

Guidance, Outlook, and Risks

Management Commentary and Outlook

• Commercialization: Management is focused on establishing Revuforj as the preferred menin inhibitor and expanding Niktimvo's market share in cGVHD. Revuforj received a second FDA approval in October 2025 for R/R AML with NPM1 mutations.
• Pipeline: The company is advancing Phase 3 trials for Revuforj in newly diagnosed AML (EVOLVE-2 and REVEAL-ND) and exploring indications in myelofibrosis. Niktimvo is being developed for newly diagnosed cGVHD and idiopathic pulmonary fibrosis (IPF).
• Liquidity: As of December 31, 2025, the company held $394.1 million in cash and investments, which management believes is sufficient to fund operations for at least the next 12 months.

Risks and Contingencies

• Profitability: The company has incurred net losses since inception (except 2021) and anticipates continued losses as it scales commercialization and R&D.
• Regulatory and Clinical: Success depends on the outcomes of ongoing Phase 3 trials and the ability to obtain additional regulatory approvals. Failure to meet endpoints could halt development.
• Collaboration Dependence: Commercial success of Niktimvo relies heavily on Incyte's performance. Incyte may deprioritize the program or terminate the agreement.
• Intellectual Property: The company relies on licensed IP from Vitae (AbbVie) and UCB. Termination of these licenses would prevent further development or commercialization of Revuforj and Niktimvo.
• Reimbursement: Market acceptance depends on coverage and adequate reimbursement from third-party payors, which remains uncertain for new therapies.

Key Facts for Investor Verification

• Revenue Sustainability: Verify the trajectory of Revuforj and Niktimvo sales to ensure they can offset the high burn rate ($445M operating expenses) and reduce the net loss.
• Cash Runway: Confirm the $394.1 million cash balance is sufficient to fund the aggressive Phase 3 trial programs and commercial expansion without immediate dilutive equity raises.
• Collaboration Terms: Review the specific profit-sharing mechanics with Incyte for Niktimvo and the milestone payment obligations to UCB and Vitae (AbbVie) to understand future cash outflows.
• Royalty Financing Impact: Assess the long-term impact of the $350 million Royalty Pharma deal, including the 13.8% royalty rate on Niktimvo sales and the $822.5 million cap.
• Clinical Trial Data: Monitor upcoming data readouts from the EVOLVE-2 and REVEAL-ND trials for Revuforj, as these are critical for label expansion and long-term value.